Erratum: Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study

Correction to: British Journal of Cancer (2009) 101, 598–604. doi:10.1038/sj.bjc.6605218 www.bjcancer.com

Upon publication of this paper in Volume 101, the authors noticed an error in the data contained within Table 3, taken from their original manuscript. The incidence of alopecia in CMF group should have been 39.3%, not 9.3%. The correct data are now shown, below.

Table 1 Adverse events

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

Additional information

The online version of the original article can be found at 10.1038/sj.bjc.6605218

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Park, Y., Okamura, K., Mitsuyama, S. et al. Erratum: Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. Br J Cancer 101, 1031 (2009) doi:10.1038/sj.bjc.6605295

Download citation